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Objective: To evaluate the outcomes after fenestrated endovascular aortic repair (f-EVAR) in a tertiary European referral
center.
Methods: All patients treated with commercially available custom-made f-EVAR between September 2002 and June 2007
were prospectively enrolled in a computerized database including co-morbidities and aneurysm morphology. Patients
were retrospectively analyzed. Follow-up consisted of clinical examinations and computed tomography (CT) scanning.
Results:A total of 54 patients were included in this study. Median age was 72 (interquartile range [IQR] 68-76) years and
85% were men. Median preoperative aneurysm diameter was 60 (53-66) mm. One hundred thirty-four vessels were
targeted (43 scallops, 91 fenestrations) and 96 stents were placed (69 bare, 27 covered). Target vessel catheterization was
achieved in 98% of cases. Two patients (3.7%) died within 30 days, 1 from trash embolization and multiorgan failure and
1 from retroperitoneal bleeding caused by a renal artery perforation. Three type I endoleaks occurred intraoperatively,
two sealed pre-discharge and one was treated with a Palmaz stent (Cordis, Miami Lakes, Fla) on postoperative day 4.
Thirteen patients had type II endoleaks, and 2 required treatment. The median clinical follow-up was 25 (12-32) months
with median CT follow-up of 22 (4-26) months. Aneurysm diameter decreased >5 mm in 47%, was unchanged in 50%,
and increased >5 mm in 3% of patients at 1 year. There were three type II endoleaks at 1-year follow-up, one of which
was successfully treated after 19 months due to aneurysm growth. Ninety-six percent of target vessels remained patent
during the study period and all occlusions occurred within the first year of follow-up. Five target vessels occluded (2 renal
arteries [RAs] and 3 superior mesenteric arteries [SMAs]) without symptoms during follow-up and successful reinter-
ventions were done on 2 stenosed RAs. Three patients suffered creatinine increase but none needed dialysis. One late
aneurysm-related death occurred due to massive bleeding during redo surgery for infection.
Conclusion:Despite complex anatomy or severe comorbidities in these patients f-EVAR has acceptable short- and midterm
results in this series which includes a learning curve and offers a valid treatment alternative to patients unsuitable for
standard EVAR or open repair. ( J Vasc Surg 2009;49:568-75.)Randomized trials have shown endovascular aneurysm
repair (EVAR) to be a valid treatment option in patients
with asymptomatic abdominal aortic aneurysms (AAA).
This minimally invasive option offers patients a treatment
with less morbidity and mortality than conventional open
aneurysm surgery.1-3 The technique is, however, usable
only in patients with suitable proximal and distal sealing
zones. This is true in 50-70% of patients, the remaining
patients have inadequate fixation and seal in the proximal
aortic neck or iliac vessels.4,5 In order to treat patients with
inadequate proximal necks, the sealing zone of the stent
graft must be moved proximal to a healthier portion of the
aorta. The aortic visceral side branches can be incorporated
into the repair with the aid of fenestrations in the graft that
allow continued blood flow into the viscera. Since the initial
report in 1999,6 fenestrated EVAR (f-EVAR) devices have
been implanted in over 1500 patients worldwide and are
now commercially available. Limited data are published,
From the Vascular Center Malmö-Lund, Malmö University Hospital.
Competition of interest: none.
Presented at the Society for Vascular Surgery Annual Meeting, San Diego,
Calif, Jun 5-8, 2008.
Reprint requests: Thorarinn Kristmundsson, MD, Vascular Center Malmö-
Lund, Malmö University Hospital, s. forstatsgatan 101, 20502 Malmö,
Sweden (e-mail: thorark@hotmail.com).
0741-5214/$36.00
Copyright © 2009 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.10.022
568however, and data skewed due to most patients originating
from one single center series.7 The aim of this study is to
analyze the results in a single center experience of patients
treated with f-EVAR, with the main focus on target vessel
patency and short-term outcome.
METHODS
All patients treated with f-EVAR were prospectively
enrolled in a computerized database incorporatingmultiple
variables such as co-morbidities, aneurysm size, neck mor-
phology, indication for treatment, total number of fenes-
trations, and total number of stents/covered stents in
target vessels. Workup consisted of clinical exam and high-
resolution spiral computed tomography (CT) scan from
the distal thoracic aorta through the deep femoral arteries.
Preoperative cardiopulmonary workup consisted of spi-
rometry, echocardiography, and 12 lead electrocardiogram
(EKG) in all cases.
CT protocol. All preoperative CT scans were per-
formed on a 16 or 64 slice multidetector spiral CT scanner.
CT scans were reconstructed with 0.75-3 mm axial slices.
In the early experience, planning was performed on axial
and multiplanar reconstructions. In the later phase (since
2005), post-processing reconstructions and center-line-of-
flowmeasurements were performed on a dedicated vascular
three dimensional (3D) workstation (www.terarecon.com)
and done to define the circumferential as well as longitudi-
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phology including presence of thrombus, calcifications,
and angulations were assessed. Multiplanar and maximal
intensity projection reconstructions were used when neces-
sary, particularly in the presence of aortic neck angulation.
Inclusion criteria. All patients considered unfit or at
high risk for open aneurysm repair (old age, severe co-
morbidities, previous aortic reconstruction, or need for
suprarenal aortic clamping)8 with inadequate infrarenal
aortic necks were considered for f-EVAR. Necks 8 mm,
conical in shape (15% diameter change/10 mm) or
heavily thrombus lined (circumferential thrombus abutting
the renal arteries) were common indications for fenestrated
repair. Stent graft apposition at the level of the renal arteries
was mandatory (thus excluding suprarenal and thoracoab-
dominal aneurysms). In light of our previous experience,
patients with juxtarenal aneurysms unfit for infrarenal
EVAR, constitute a high risk for open surgery. Over the
study period (when we saw the good results of f-EVAR
compared to open surgery), a shift towards the endovascu-
lar approach occurred. Severe neck angulation (90°) was
the only absolute exclusion criteria. Only asymptomatic
aneurysms were included in this study.
Stent graft. The Zenith device (www.cookmedical.
com) formed the foundation of the fenestrated graft in all
cases. This is a modular stent graft where the fenestrations
are located on the most proximal tubular portion of the
stent graft. Fenestrations were designed to match the loca-
tions of the target vessel ostia and come in three basic types:
small fenestrations (6 8mm, intended for use in conjunc-
tion with a stent/covered stent in the target vessel), large
fenestrations (8 mm, with and without crossing stent
struts) and scallop fenestrations located at the most proxi-
mal portion of the fabric. The target vessels are catheterized
through the fenestrations after partial deployment of the
proximal tubular graft using access from the contralateral
common femoral artery. The stent graft repair is then
completed by extension with a bifurcated main body over-
lapping into the tubular graft and extension limbs into the
iliac arteries bilaterally (Figs 1-3). The device description
and implantation technique has been described in detail
earlier7,9,10 and has undergone various modifications over
time. Initially small fenestrations were stented selectively
and scallops not at all. This has now progressed to that all
small fenestrations and large fenestrations that do not have
crossing stent struts are routinely stented and scallops are
stented selectively depending on the target vessel incorpo-
rated and the “fit” of the graft. Technical success was
defined as exclusion of the aneurysm without signs of type
I or III endoleak at the completion angiography and cor-
rect placement of the fenestrations according to the preop-
erative plan.
Follow-up. Routine follow-up consisted of clinical
exam at 1 month and yearly thereafter. Multislice CT scan
and plain abdominal films were performed after 1 year and
yearly thereafter. Additional CT scans during the follow-up
period were done after 1 and 6 months on the first few
patients and thereafter on clinical indication only. End-points were target vessel stenosis or occlusion, secondary
intervention, or death. Endoleaks (early and late), change
in aneurysm size, and change in serum creatinine over time
were also registered. Aneurysm diameter changes were
Fig 1. Maximum intensity projection reconstruction of an aortic
aneurysm with very short infrarenal neck.
Fig 2. Fenestrated stent graft deployed with both renal arteries
catheterized and renal sheaths in place.considered significant when 5 mm.
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with interquartile range. TheWilcoxon signed rank test was
used for analyzing changes in aortic diameter during
follow-up. All cause mortality, aneurysm-related mortality,
and intervention-free survival was estimated by Kaplan-
Meier and life table analysis. SPSS for windows version 13.0
(SPSS Inc, Chicago, Ill, www.spss.com) was used for all
statistical analysis. A P  .05 was considered statistically
significant.
RESULTS
A total of 54 patients were treated with custom ordered
fenestrated stent grafts between September 2002 and June
2007. During the same period, 47 asymptomatic patients
underwent open repair for juxtarenal aortic aneurysms. The
present series consisted of 46 men and 8 women with a
median age of 72 (68-76) years. The preoperative risk
factors are listed in Table I. The indication for treatment
was AAA in 44 patients, residual AAA after open aneurysm
surgery in 3 patients, aortic ulceration in 3 patients, residual
AAA after conventional infrarenal EVAR in 2 patients, and
aortic dissection with a secondary aneurysm in 2 patients.
All patients included in the study were asymptomatic,
deemed unsuitable for open surgery, and had either a short
aneurysm neck (8 mm), were anatomically unsuitable for
a traditional infrarenal EVAR due to poor proximal necks,
or considered at increased risk for open repair. Median
aortic diameter was 60 (53-66)mmon the preoperative CT
scan, 54 (46-64) mm after 12 months, and 53 (43-66) mm
after 24 months. The reduction of the aortic diameter at 12
months was statistically significant (P  .001). The aneu-
rysm diameter decreased 5 mm in 47% of patients at 1
Fig 3. Final angiogram showing good flow through renal stents
and in superior mesenteric artery (SMA) which was incorporated
into the graft with a non stented, reinforced scallop.year, increased 5 mm in 3%, and remained stable in 50%.A total of 134 fenestrations/scallops (91 fenestrations,
43 scallops) were incorporated in the prosthesis design
(mean 2.5 per patient) with a total of 96 stents/covered
stents placed into target vessels. Table II shows the distri-
bution of renal, superior mesenteric, and celiac arteries
involved.
Primary technical success was achieved in 49 patients.
Median procedure time was 250 (210-333) minutes with
a median fluoroscopy time of 78 (59-108) minutes. The
median volume of contrast utilized was 270 mL with a
median iodine dose of 53 g/patient. Percutaneous ap-
proach to the common femoral artery was used in 88 groins
(44 patients) with failure in 12 groins (9 patients) requiring
conversion to open surgery in order to secure hemostasis or
adequate lower extremity circulation. Median blood loss
was 600 (400-1000) mL with median volume of transfused
blood products of one unit per patient (0-3).
Endoleaks. The use of large balloon-expandable
stents (Palmaz) to treat type I (n 11) or type III (n 3)
endoleak (at the overlap between the first and second graft
component) was required in 13 patients. Completion an-
giography showed type I endoleaks in 3 patients, 2 proxi-
mal and 1 distal. In the 2 cases with proximal leaks, these
had resolved on pre-discharge CT scans at 2 and 5 days
postoperatively. In the third case, a distal endoleak was
treated with a Giant Palmaz stent in the right iliac artery on
postoperative day 4. Type II endoleaks were observed in 13
patients on completion angiography and persisted in 3
Table I. Pre-operative co-morbidities and risk factors
Patients (n) %
Diabetes 7 13
Previous MI 19 35
Angina 13 27
Congestive heart failure 7 13
Arterial hypertension 34 62
COPD 21 38
Renal insufficiency (creatinaemia
105 mol/L) 24 44
MI, Myocardial infarction; COPD, chronic obstructive pulmonary disease.
Table II. Distribution of vessels incorporated into the
fenestrated devices
Mesenteric fenestrations/Scallops
Number of renal
fenestrations
0 1 2 3
None 8 9
SMA 1 3 29 1
SMA  Celiac 1 2
SMA, Superior mesenteric artery.
Majority of patients (54%) had devices involving the two main renal arteries
and the SMA (94 renal arteries with 62 stents and 25 covered stents placed,
37 SMAs with 7 stents and 2 covered stents placed and 3 celiac arteries with
no stents or covered stents placed). Two patients had devices incorporating
all four visceral vessels.patients at 1 year. One patient was successfully treated with
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days (endoleak on 1-month CT scan) and another with
glue embolization of lumbar arteries after 553 days (ex-
panding aneurysm sac). No other type II endoleaks were
treated. One patient had a type III endoleak on the com-
pletion angiography but died from complications due to
bowel ischemia prior to any control angiography.
Target vessel patency. Patency during the follow-up
period was achieved in 129 of 134 target vessels. Those
vessels which stenosed or occluded during follow-up did so
within the first 12 postoperative months. Two unstented
renal arteries early in the series became partially covered by
the stent graft fabric without causing a hemodynamically
significant stenos or occlusion during the follow-up period.
Five target vessels occluded either during surgery or follow-
up. In one case, a Giant Palmaz stent was placed over the
left renal artery during the primary procedure in order to
seal a proximal type I endoleak where the renal artery
already had a reduced blood flow secondary to a guidewire-
induced dissection. One dissection distal to a stent in a renal
artery was left untreated. The artery was stented primarily
but the completion angiography showed a short dissection
distal to the stent (into a renal artery branch) without
affecting the blood flow to the rest of the kidney. The vessel
occluded prior to the 12-month CT scan. Three superior
mesenteric arteries (SMAs) occluded during the follow-up
period. All had a scallop and were unstented primarily. Two
were found to be occluded on a 12-month CT scan and one
6 month’s postoperatively. In all cases, the patients were
asymptomatic and no further intervention was necessary.
Redo percutaneous transluminal angioplasty (PTA) was
performed on two stented renal arteries which showed
stenoses on the 1-year CT scan with successful assisted
primary patency in both cases. Two other stented renal
arteries had significant stenosis on 1-year CT follow-up and
were not treated. In one case, the patient had disseminated
malignant disease and in the other case the kidney had
shrunken and was non-functional at the time of diagnosis.
Renal function. The median preoperative creatinine
level in the female group was 94 (67-98) mol/L (normal
level 45-90 mol/L) and in the male group 103 (88-141)
mol/L (normal level 60-105mol/L). Nineteen patients
(35%) developed at least a transient increase in serum
creatinine30% in the immediate postoperative period. All
improved during follow-up with a decrease below the 30%
barrier in 16 cases (84%). Five patients with normal post-
operative creatinine levels developed an increase 30%
later during follow-up without any signs of reduced renal
blood flow or stenoses on their CT scans. Two renal arteries
were treated for stenoses (see previous section) without
measurable signs of decreased renal function. Two patients
died within 30 days from the procedure and both showed
a significant elevation of serum creatinine (252-505mol/L)
as part of multiorgan failure. One patient was on dialysis
prior to endografting and no other patient became dialysis-
dependent during follow-up.
Survival. The median clinical follow-up was 25 (12-
32) months with a median CT follow-up of 22 (4-26)months. Twelve patients died during the follow-up period
and 2 of those within 30 days of the initial procedure
(3.7%). One patient developed bowel ischemia secondary
to mesenteric artery embolization and died after 13 days
from multiorgan failure. One patient died after 15 days
from complications secondary to retroperitoneal bleeding.
The patient had extremely difficult renal access during the
operation due to neck angulation thus necessitating the use
of an extra stiff wire in the renal artery for sheath placement.
On sheath advancement, the stiff wire caused a renal per-
foration. This was unfortunately missed intraoperatively.
Postoperative hemodynamic instability prompted a CT
scan that revealed a retroperitoneal bleed. The patient died
despite an effort to control the bleeding. One patient died
frommassive bleeding at an outside hospital 6 months after
the primary procedure during surgery of the groin related
to infection. No other deaths were aneurysm related. Figs 4
and 5 show the survival function for all cause mortality and
intervention-free survival.
DISCUSSION
Infrarenal EVAR is a valid option to open surgical
repair (OR) with many benefits for the patients.2,3 How-
ever, anatomical limitations in the proximal aneurysm neck
exclude EVAR in 20-30% of patients. In contrast to OR,
where a clamp can be placed suprarenally but the repair
performed infrarenally, EVAR requires a good infrarenal
neck for durable fixation and seal. In patients with unsuit-
able infrarenal necks, the concept of f-EVAR has been
shown to be feasible.11 By customizing a stent graft with
fenestrations for the mesenteric arteries, one can utilize a
healthier more proximal portion of the aorta as a sealing
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Fig 4. Kaplan-Meier estimate of the survival function for all cause
mortality with numbers at risk inside the box. Twelve patients died
during the follow-up period and 2 of those within 30 days of the
initial procedure (3.7%). In total, three deaths were aneurysm-related.and fixation zone.
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are limited except for the vast experience from the Cleve-
land Clinic. Operative mortality in these and other pub-
lished reports vary from 0.4-2.6%.7,12-17 The mortality in
our series is higher at 3.7%, the reason for this is unclear and
might be due to patient selection and the small number of
patients in the series. In addition, during the learning curve
of our experience, patients with quite severe neck angula-
tion were accepted and this increases the level of difficulty
both with regard to accurate planning of the graft as well as
the actual implant. Furthermore, the introduction of a
dedicated 3D workstation using center line of flow (CLF)
reconstructions, has greatly improved the accuracy of stent
graft planning. The patients that died in our series did so of
seemingly technical causes. One patient displayed massive
embolization that causedmultiorgan failure and death. The
second patient suffered a retroperitoneal bleed due to a
renal perforation and succumbed from this despite attempts
to control the bleeding. These cases indicate that the addi-
tion of fenestrations to the stent graft procedure adds a level
of complexity, which incurs an additional risk for the pa-
tient. In particularly complex cases, a multitude of catheters
and wires may be left inside the patient for an extended
period of time increasing the risk of embolization occur-
ring. Target vessels that are hard to catheterize sometimes
require the use of stiff guidewires to achieve stable positions
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Fig 5. Kaplan-Meier estimate of the re-intervention free survival
with numbers at risk inside the box. During the first year of
follow-up, two endoleaks (type I and II, respectively) were treated.
One renal artery was embolized secondary to amassive bleeding on
the first postoperative day. The patient died of complications. One
patient developed acute ischemia in the right leg and was treated
with thrombectomy and patch in the common femoral artery on
postoperative day 115. The reason was stenos secondary to a
Perclose suture. During the second year, one type II endoleak was
treated and percutaneous transluminal angioplasty (PTA) was
done on two stenosed renal arteries.for stent delivery. These circumstances add to the difficultyand higher risk of the procedure. Given this, the results are
still comparable to those achieved from open infrarenal
repair in randomized trials.2,18 In addition, a number of the
patients treated in ours and the other reported series would
probably have needed a more proximal open repair, due to
the lack of infrarenal neck, which would likely affect the
outcome negatively. Like previous studies have shown, the
survival benefit after endovascular repair in patients unfit
for open surgery is still questionable. This is also reflected in
the 22% mortality at 2 years in our series, which is similar to
the mortality rate of an unselected cohort of infrarenal
aneurysm patients not receiving treatment.
Despite that, there are indications that patients not
anatomically suitable for standard EVAR carry a higher
rupture risk than those who are.19 This may justify fenes-
trated repair in high-risk patients as in our series. We also
believe that with increasing experience with fenestrated
endografting, we will be able to identify those patients that
are less likely to benefit from the repair and subsequently
improve the results further.
Despite the increased complexity compared to standard
EVAR, and considering that this and other reports include
the learning curve of f-EVAR, the procedural and fluoro
times are not prohibitive. The vast majority of target vessels
are successfully catheterized during the procedure without
any damage occurring. The target vessel patency in our
series was 96% with a mean follow-up approaching 2 years
and this is similar to other reports.11 The need of excellent
preoperative planning for these procedures cannot be over-
emphasized. High-quality multidetector CT scans with
thin slice reconstructions are mandatory to provide ade-
quate preoperative information. As stated, we now rou-
tinely plan these cases in a 3D workstation. This allows for
very precise determination of relationships between fenes-
trations both longitudinally and rotationally. Planning us-
ing only axial CT reconstructions is tedious and imprecise
and is not recommended. With correct preoperative plan-
ning these procedures are made significantly easier and fully
automated systems for this are currently being investigated
(Personal Communication Dr Roy Greenberg, Cleveland
Clinic Foundation, Cleveland, Ohio). The largest issue is to
estimate the interface between the endografts and the
aorta, a fact that can significantly affect the relationship
between the fenestrations and the target vessels. This takes
some experience especially in the setting of very angulated
aortas and infrarenal necks.
Like other authors have noted,7,13,16,20,21 there seems
to be increased risk of target vessel occlusion in unstented
fenestrations. Previously these have been described mainly
for unstented scallops for the renal arteries, but a recent
report from the Liverpool group has also noted the phe-
nomenon for the SMA.21 We had three cases of postoper-
ative asymptomatic SMA occlusions in unstented SMA
scallops. The reason for this was probably misalignment of
the graft after deployment. During the catheterization pro-
cess, the graft is constrained by diameter-reducing ties on
the posterior aspect of the stent graft. This is to achieve a
space between the graft and the aortic wall and to alleviate
JOURNAL OF VASCULAR SURGERY
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successful target vessel catheterization and sheath place-
ment, the graft is released and tracks over the sheaths to
oppose the aortic wall. Thus, any fenestration that is not
secured by sheath access runs the risk of misaligning after
deployment. Whereas the positioning of the target vessel
craniocaudally within an unstented fenestration is often
easy to determine, a rotational misalignment is hard to
visualize and detect. A discrete misalignment intraopera-
tively may lead to partial covering of the target vessel
(shuttering), reducing flow, and subsequently leading to an
occlusion. We have now adopted a policy of liberal use of
stents in deep scallops for the SMA. Fenestrations are
always stented. If the planning identifies a high risk of SMA
compromise, a safety wire is placed through a brachial
approach leaving the option to stent the SMA after deploy-
ment, should this be necessary.
One concern regarding fenestrated stent graft is the
potential effect on renal function. This has been well de-
scribed by the group at the Cleveland Clinic and they noted
some effect on renal function in about a fifth of their
patients postoperatively.7,9,22 Reports on conventional
EVAR also report a deterioration in renal function after
EVAR regardless of whether bare fixation stents across the
renal arteries are used or not.23-25 It is well known after
open repair that renal function is affected negatively in the
immediate postoperative period in a large number of pa-
tients. Series that have compared open and endovascular
repair report conflicting results, most likely due to selection
bias. Renal status is also negatively correlated to longer time
and more proximal clamp positioning.26,27 Logically the
same phenomenon is seen after EVAR. In this series, 30% of
patients had transient creatinine increase postoperatively
but only 16% of these had permanent increase in creatinine,
which was still within normal limits. No patient required
dialysis. In a small number of patients, renal function
deteriorated during follow-up without signs of renal artery
stenosis. This might very well be the result of natural
progression of disease in these patients.
Like most endovascular treatments, f-EVAR has the
appeal of the minimally invasive approach and data until
now seem to confirm that this technology works in the
short- to midterm. Obviously further long-term follow-up
is needed and the ultimate answer to find the right treat-
ment for these patients depends on continued close obser-
vation and technological development. To be able to
achieve good results with this technology, however, certain
prerequisites must be met: (1) the quality of the preopera-
tive imaging needs to be significantly better than for stan-
dard EVAR or open repair, including appropriate 3D im-
aging capabilities. The importance of good preoperative
graft planning cannot be emphasized enough. (2) Even
though the skills required for fenestrated endografting are
no different from other complex endovascular interven-
tions, these procedures require a wider range of endovas-
cular tools than standard EVAR and, in most cases, also
intraoperative imaging of higher standard than most mo-
bile C-arms can offer. (3) The volume of patients thatqualify for f-EVAR might be in the range of 10-20% of a
total standard AAA practice. Thus the numbers will, in
most centers, be fairly low and this might affect results
negatively.
Certain patient characteristics should be identified as
they might increase the difficulty of the procedure. In our
experience, the presence of much angulated necks, very
tortuous, narrow or calcified iliacs, and especially any com-
bination of these features increases the difficulty substan-
tially. The reason is that stent graft orientation during the
procedure is crucial and these features severely inhibit stent
graft manipulation within the aorta. If one or several of
these features are present, other treatment options should
be considered and fenestrated endografting should only be
undertaken by very experienced operators.
CONCLUSION
f-EVAR is a procedure with good short- and midterm
results that offer a valid treatment alternative to patients
unsuitable for standard EVAR or open repair. Further
development of procedure specific devices, improved pre-
operative planning, and better understanding of the stent
graft to native aorta interaction might improve results in
the future.
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Dr Hasan Dosluoglu (Buffalo, NY). In light of the previous
paper, it will be interesting to see what percent of your patients
were in the high-risk category. So could you please break down
those who were physiologically high risk vs those who weren’t?
What was your mortality in each group? I understand that it was
20% for the entire cohort. Was there a difference between groups
and could you identify a subgroup that you, in retrospect, would
have preferred not to have done anything?
Dr Thorarinn Kristmundsson. The definition of high risk is
a little bit complicated, but that’s a definition by the surgeon and
the anesthesiologist. Many of these patients have had previous
aortic surgery or severe comorbidities and the need for suprarenal
clamping was also considered high risk. We haven’t done any
subgroup analysis to identify risk factors.
Dr Peter Gloviczki (Rochester, Minn). Your group should be
congratulated for pushing the envelope and developing this pro-
cedure in patients who are really high risk or unfit for surgery
repair.
My question is somewhat related to the previous one, because
you said that these were all high-risk patients or unfit for surgery.
Dr West, from our group, reported in 2006 in the Journal of
Vascular Surgery about his 10 year Mayo Clinic experience with
247 patients with a perioperative mortality of 2.8% who had
supraceliac clamping and required aortic aneurysm repair because
of juxtarenal and suprarenal aneurysms. So there are quite a large
number of patients who can undergo open surgery with a very
decent mortality.
So I am wondering, when you take all your patients with this
anatomy, how many of those did you do open, and how many didguidelines on who are the patients suitable for your procedure and
if the technology is there to do endovascular repair in good risk
patients?
Dr Kristmundsson. During this period of time, we did about
50 patients with an open approach at our clinic. I want to congrat-
ulate you on these excellent results that you have at the Mayo
Clinic. In our clinic, when we do open surgery with suprarenal
clamping of patients that are anatomically unfit for conventional
EVAR or infrarenal clamping, we have a mortality of about 10% to
15% in the first 30 days of the procedure. So it’s a high risk.
Dr Gloviczki. The operation alone is high risk?
Dr Kristmundsson. Yes.
Dr Timothy Resch. Again, we’ve published the data from
Malmö on our patients. And if you look at standard infrarenal
repairs, the results are excellent for the open group with 0%
mortality.
But as Dr Kristmundsson pointed out, if you look at the
patient cohort included here, and I think that was why we went to
this endeavor of doing fenestrated endografts with patients that
had physiological high-risk criteria: renal or congestive heart fail-
ure, other complicating factors, or the mere risk of having a
supraceliac clamp, we were, quite frankly, abhorred with our own
experience. We would have liked to send most of our patients to
the Mayo Clinic. Unfortunately, it’s a fairly long trip. So in light of
that, we’ve used the fenestrated endografts for most of those
patients and we think they’re doing reasonably well.
Dr Luiz Lanziotti (Rio de Janeiro, Brazil). We’ve been
involved with fenestrated endografts for juxtarenal AAA, as well as
branched endografts for thoracoabdominal aneurysm in Rio, and I
noticed you had three SMA occlusions. One of the worries we have
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identified any possible technical issues that might have caused these
occlusions? Regarding clinical outcomes on these patients, how
have you identified them and did these patients have previous
inferior mesenteric or celiac artery occlusion as well? Did that
influence? What are your insights on that?
Dr Kristmundsson. I think that the main problem is that
when you place the scallop for the SMA, there is a risk for a
rotational misalignment. So you can get a portion of the fabric that
lies over the ostia. And that has been reported by other groups as
well. So what we do now is we use a liberal use of stents in deep
scallops for the SMAs, and we tried to avoid this problem that way.
These patients that had SMA occlusions were asymptomatic,
and we found them during routine follow-up at 1 year and 6
months.
Dr Lanziotti. So were any of those stented patients or all
three SMA occlusions were scallop-related?
Dr Kristmundsson. All three were from scallops and all three
were unstented.
Dr Resch. When we use covered stent, we use Atrium Ad-
venta, and for the renal stents we use the Bridge Assurant, but you
can use various kinds of stents.
For the SMA, the issue becomes a little bit trickier, as I’m sure
others will mention, because of the sharp angle take-off, especially
if you’re going for the SMA from below. You’ll have a very poor
angle of approach and you run a fairly high risk of causing adissection distally in the SMA when you do the procedure, so
whether to use the self-expanding or balloon-expandable stent
remains to be proven.
Dr Timothy Chuter (San Francisco, Calif ). To clarify the
point about selection of high-risk patients. I was fortunate enough
to have the opportunity to see the paper on which this presentation
was based. One of the things I noted was that 47 patients under-
went open repair with suprarenal clamps during the period of this
study, which indicates that roughly half the patients who required
a suprarenal clamp underwent endovascular procedures and
roughly half underwent open surgical procedures. Assuming that
the primary triage criterion between open and endovascular treat-
ment was anesthetic risk, the endovascular group truly were high-
risk.
This series covered a long period of time and the insertion of a
fenestrated stent graft can be a complex operation. I suspect that
your skills evolved during that time. Did you notice any difference
between early results and late results?
Dr Kristmundsson. During the time of the study, the first
year, we only did 1 patient with one fenestration. The cases are
getting more and more complicated every year, as we see as the
average number of fenestrations in 2007 is 3.1 per patient. In
addition, the patients are getting older and sicker. However, we
didn’t do any subanalysis on the outcomes between the different
time periods.
